15 Fastest Growing Biotech Companies in the US
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US.
Biotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living organisms to make new treatments and technology for healthcare. Advances in biotechnology are stepping stones for human progress in key areas like genetics, DNA sequencing, recombinant gene techniques, applied immunology and diagnostics. Data shows that global biotechnology market is expected to cross $720 billion in value by 2025.
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for efgartigimod in generalized myasthenia gravis (gMG)
Initiated 50-patient gMG bridging study of subcutaneous (SC) efgartigimod based on FDA feedback
Enrolled first 30 patients, necessary for go/no-go decision, in ADHERE trial of SC efgartigimod for chronic inflammatory demyelinating polyneuropathy (CIDP)
Announced interim data from Phase 2 CULMINATE trial of cusatuzumab in development with Janssen
Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted recent achievements fro
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
Zai Lab Limited; argenxJanuary 6, 2021 GMT Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each year Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China
argenx to receive $75 million in upfront Zai Lab equity and $100 million in near-term milestone and other payments
Regulated Information/Inside Information
BREDA, the Netherlands and SHANGHAI and SAN FRANCISCO, Jan. 06, 2021 (GLOBE NEWSWIRE) argenx SE (Euronext & NASDAQ: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage
[December 28, 2020]
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China s National Reimbursement Drug List
SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has been included in the updated National Reimbursement Drug List (NRDL) released by Chinaâs National Healthcare Security Administration (NHSA). ZEJULA (niraparib) is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor with national Category 1 designation. It has been included in the NRDL as maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.